The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000782336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
12/05/2026
Date registered
Help: Date registered
30/06/2026
Date last updated
Help: Date last updated
30/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot and pragmatic study evaluating the use of domiciliary humidified nasal high flow therapy in patients with frequent exacerbations of chronic lung disease
Scientific title
A pilot and pragmatic study evaluating the effect of domiciliary humidified nasal high flow therapy on respiratory rate in patients with frequent exacerbations of chronic lung disease
Additional trial identifiers [1] 317212 0
Nil
Universal Trial Number (UTN)
Trial acronym
RELIEF-High Flow Study - Randomized Evaluation of Long-term Integrated Enhanced Flow therapy
Related trial records

Health condition
Health condition(s) studied:
Chronic obstructive pulmonary disease (COPD) 341806 0
Asthma 341807 0
Bronchiectasis 341808 0
Interstitial lung disease 341809 0
Condition category
Condition code
Respiratory 337877 337877 0 0
Chronic obstructive pulmonary disease
Respiratory 337878 337878 0 0
Asthma
Respiratory 337879 337879 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants on the intervention arm will receive humidified nasal high flow therapy (NHF) for at least 4 hours a day (preferably overnight) in their homes for 4 weeks of intervention period prior to crossing over to their standard care.

Device specifications:
o Device: myAIRVO device by Fisher & Paykel Healthcare
o Interface: nasal cannula (sized and fitted to patient to minimise air leak and discomfort with the aim of using largest size appropriate with a clear gap around each prong)
o Flow rate: starting at 15L/min up to 60L/min, titrated to comfort??
o Humidification: temperature set between 34 and 37 degrees Celsius and titrated for comfort
o FiO2:
- If not on supplemental oxygen: FiO2 ~21% (room air)
- If already on supplemental oxygen: fixed FiO2 as per pre-trial oxygen prescription (not titrated)

Device set up and training:
o Vital detect, under mattress sensor and other study equipment / paperwork will be delivered to all participants homes at the start of trial and for those starting on intervention arm, the NHF device will also be delivered at the same time by the respiratory nurses. NHF will be delivered prior to intervention period for those starting on standard care.
o Set up and education by home respiratory nurses at the time of device delivery. Approximately an hour will be allocated for this.
o Education will be provided on device use and troubleshooting, cleaning and maintenance and when to seek help

Throughout the trial, this respiratory rate, heart rate, peripheral oxygen saturation, symptoms and quality of life questionnaires will be monitored. Adherence can be monitored via the data uploaded to online server, but participants will not be routinely contacted to encourage adherence.
Intervention code [1] 334042 0
Treatment: Devices
Description of the comparator or control
This is a crossover trial, so participants will serve as their own controls.
- Trial period: 1 week of baseline monitoring -> 4 weeks of intervention or monitoring on standard care -> 1 week washout period -> 4 weeks of intervention or monitoring on standard care

Standard care essentially implies participants are monitored whilst receiving their usual treatment without any study intervention.
Control group
Active

Outcomes
Primary outcome [1] 345390 0
Respiratory rate
Timepoint [1] 345390 0
Monitor it twice a day throughout study period (irrespective of intervention vs standard care) which is total 10 weeks.
Secondary outcome [1] 461491 0
Number of exacerbations
Timepoint [1] 461491 0
Throughout the 10-week study period
Secondary outcome [2] 461492 0
Time to first event of exacerbation
Timepoint [2] 461492 0
Throughout the 10-week study period
Secondary outcome [3] 461500 0
Health related quality of life
Timepoint [3] 461500 0
Baseline and end of 4-week intervention (which can be 5-weeks into study period or 10-weeks depending on which arm participants start)
Secondary outcome [4] 461502 0
Sleep quality
Timepoint [4] 461502 0
Baseline and end of 4-week intervention (which can be 5-weeks into study period or 10-weeks depending on which arm participants start)
Secondary outcome [5] 461503 0
Heart rate
Timepoint [5] 461503 0
Twice daily for the 10-week trial duration
Secondary outcome [6] 461504 0
Peripheral oxygen saturation
Timepoint [6] 461504 0
Twice daily for the 10-week trial duration
Secondary outcome [7] 461505 0
Step count
Timepoint [7] 461505 0
Daily for the 10-week trial duration
Secondary outcome [8] 461506 0
Adherence to intervention
Timepoint [8] 461506 0
Will be reviewed at the end of intervention (which can be 5-weeks into study period or 10-weeks depending on which arm participants start)
Secondary outcome [9] 462390 0
Health related quality of life
Timepoint [9] 462390 0
Baseline and at the end of intervention (which can be 5-weeks into study period or 10-weeks depending on which arm participants start)
Secondary outcome [10] 462391 0
Severity of breathlessness
Timepoint [10] 462391 0
Baseline and at the end of intervention (which can be 5-weeks into study period or 10-weeks depending on which arm participants start)
Secondary outcome [11] 462393 0
Sleep quality
Timepoint [11] 462393 0
Baseline and at the end of intervention (which can be 5-weeks into study period or 10-weeks depending on which arm participants start)
Secondary outcome [12] 462398 0
Breathing difficulty
Timepoint [12] 462398 0
Daily throughout the study period of 10 weeks
Secondary outcome [13] 462399 0
Sputum production
Timepoint [13] 462399 0
Daily throughout the 10 week study period
Secondary outcome [14] 462402 0
Sputum thickness
Timepoint [14] 462402 0
Daily throughout the 10 week study period
Secondary outcome [15] 462403 0
Sputum colour
Timepoint [15] 462403 0
Daily throughout 10 week study period
Secondary outcome [16] 462405 0
Cough
Timepoint [16] 462405 0
Daily throughout 10 week study period
Secondary outcome [17] 462407 0
Tiredness
Timepoint [17] 462407 0
Daily throughout 10 week study period
Secondary outcome [18] 462410 0
Wheeze severity
Timepoint [18] 462410 0
Daily throughout 10 week study period
Secondary outcome [19] 462413 0
Chest tightness
Timepoint [19] 462413 0
Daily throughout 10 week study period
Secondary outcome [20] 462414 0
Nose congestion
Timepoint [20] 462414 0
Daily throughout 10 week study period
Secondary outcome [21] 462422 0
Steroid use
Timepoint [21] 462422 0
Daily throughout 10 week study period
Secondary outcome [22] 462424 0
Inhaler or nebuliser use
Timepoint [22] 462424 0
Daily throughout 10 week study period

Eligibility
Key inclusion criteria
• age 18 years or older,
• clinically diagnosed with COPD (stable, hypoxaemic and/or hypercapnic), asthma, bronchiectasis, CPFE, ILD or other chronic respiratory disease at the investigator’s discretion,
• must have had 2 or more respiratory related hospital admissions in 12 months,
• managed by respiratory integrated care services (RICS),
• clinically stable at the time of recruitment,
• participant or carer need to be able to set up / use device following education,
• must be able to provide informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• unable to provide informed consent,
• severe cognitive impairment or unstable psychiatric illness that will interfere with provision of NHF therapy,
• exacerbation 1 week prior to recruitment,
• contraindication to using humidified nasal flow therapy such as severe facial/nasal trauma,
• already using positive airway pressure device (NIV or CPAP).

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321789 0
Hospital
Name [1] 321789 0
Flinders Medical Centre
Country [1] 321789 0
Australia
Funding source category [2] 322276 0
Commercial sector/Industry
Name [2] 322276 0
Fisher and Paykel
Country [2] 322276 0
Australia
Primary sponsor type
Hospital
Name
Flinders Medical Centre
Address
Country
Australia
Secondary sponsor category [1] 324701 0
None
Name [1] 324701 0
Address [1] 324701 0
Country [1] 324701 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320333 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 320333 0
Ethics committee country [1] 320333 0
Australia
Date submitted for ethics approval [1] 320333 0
16/02/2026
Approval date [1] 320333 0
Ethics approval number [1] 320333 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150122 0
Dr Bridget Joseph Xavier
Address 150122 0
Flinders Medical Centre, Flinders Dr, Bedford Park SA 5042
Country 150122 0
Australia
Phone 150122 0
+61 8 82045511
Fax 150122 0
Email 150122 0
Contact person for public queries
Name 150123 0
Bridget Joseph Xavier
Address 150123 0
Flinders Medical Centre, Flinders Dr, Bedford Park SA 5042
Country 150123 0
Australia
Phone 150123 0
+61 8 82045511
Fax 150123 0
Email 150123 0
Contact person for scientific queries
Name 150124 0
Bridget Joseph Xavier
Address 150124 0
Flinders Medical Centre, Flinders Dr, Bedford Park SA 5042
Country 150124 0
Australia
Phone 150124 0
+61 8 82045511
Fax 150124 0
Email 150124 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.